Immunocore to present at upcoming investor conferences
12 9월 2023 - 6:00AM
Immunocore to present
at upcoming investor
conferences
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn.
& ROCKVILLE, Md., US, 11 September 2023) Immunocore Holdings
Plc (Nasdaq: IMCR), a commercial-stage biotechnology company
pioneering the development of a novel class of T cell receptor
(TCR) bispecific immunotherapies designed to treat a broad range of
diseases, including cancer, infectious diseases and autoimmune
conditions, today announced that management will present at the
following investor conferences in September:
- H.C. Wainwright Healthcare
Conference Fireside Chat: Monday, September 11, 2023, at
2:30 p.m. EDT
- Morgan Stanley Healthcare
ConferenceFireside Chat: Tuesday, September 12, 2023, at
5:30 p.m. EDT
- Baird Healthcare
Conference1x1 and small group meetings: Wednesday,
September 13, 2023
- 2023 Cantor Global
Healthcare ConferenceFireside Chat: Thursday, September
28, 2023, at 8:00 a.m. EDT
Where relevant, the presentations will be
webcast live and can be accessed by visiting ‘Events’, under ‘News
& Events’, via the ‘Investors’ section of Immunocore’s website
at www.immunocore.com. Following the events, a replay of the
presentations will be made available for a limited time.
##
About Immunocore
Immunocore is a commercial-stage biotechnology
company pioneering the development of a novel class of TCR
bispecific immunotherapies called ImmTAX – Immune mobilizing
monoclonal TCRs Against X disease – designed to treat a broad range
of diseases, including cancer, autoimmune, and infectious disease.
Leveraging its proprietary, flexible, off-the-shelf ImmTAX
platform, Immunocore is developing a deep pipeline in multiple
therapeutic areas, including four clinical stage programs in
oncology and infectious disease, advanced pre-clinical programs in
autoimmune disease and multiple earlier pre-clinical programs. The
Company’s most advanced oncology TCR therapeutic, KIMMTRAK has been
approved for the treatment of HLA-A*02:01-positive adult patients
with unresectable or metastatic uveal melanoma in the United
States, European Union, Canada, Australia, and the United
Kingdom.
CONTACT:
Immunocore Sébastien Desprez, Head of
CommunicationsT: +44 (0) 7458030732E:
sebastien.desprez@immunocore.comFollow on Twitter: @Immunocore
Investor Relations Clayton Robertson,
Head of Investor RelationsE: ir@immunocore.com
Immunocore (NASDAQ:IMCR)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Immunocore (NASDAQ:IMCR)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
